Many companies are announcing agentic AI for drug asset scouting. Very few are publishing rigorous, data-supported research on how it performs.
This week, we released a new Bioptic paper on AI-driven drug asset scouting, co-authored with Luba Greenwood, advisor to Bioptic and former Head of M&A at Roche, former Head of Business Development at Verily, and former Managing Partner at Dana Farber Ventures.
Asset scouting shapes portfolio strategy, capital allocation, and long term competitive positioning. It requires synthesizing signals across clinical trials, patents, publications, regulatory updates, and competitive moves. In this paper, we share the datasets, evaluation framework, and benchmark results behind our approach.
We measure recall, completeness, and decision relevance using a vertical, pharma-specific agentic system. The criteria reflect real world scouting standards informed by one of the most experienced leaders in pharma M&A.
We believe AI in high stakes industries should be evaluated with the same precision as the decisions it supports. Read the full paper to see how we stand behind that commitment.
.png)